Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobus Pfisterer

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Krankenpflege Journal|May 1, 2004
[Therapy of advanced ovarian carcinoma]Jacobus Pfisterer
The Lancet. Oncology|February 2, 2013
Towards individualised treatment in ovarian cancerSven Mahner, Jacobus Pfisterer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Reply to R. Sun et alJacobus Pfisterer, Joern Rau
Seminars in Oncology|May 24, 2006
Management of platinum-sensitive recurrent ovarian cancerJacobus Pfisterer, Jonathan A Ledermann
Current Treatment Options in Oncology|May 1, 2020
Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?Joanna Glajzer, Jacek P Grabowski, Jalid Sehouli, et al.
Immunotherapy|February 17, 2011
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancerRachel N Grisham, Jonathan Berek, Jacobus Pfisterer, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All?Leigh A Cantrell, Jacobus Pfisterer, John Boggess, et al.
Gynecologic Oncology|November 8, 2008
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic reviewAndreas du Bois, Justine Rochon, Jacobus Pfisterer, et al.
Gynecologic Oncology|September 24, 2004
The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter studyEva-Katrin Riener, Norbert Arnold, Friedrich Kommoss, et al.
Onkologie|March 15, 2012
Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experienceFelix Hilpert, Pauline Wimberger, Andreas du Bois, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Krankenpflege Journal|May 1, 2004
[Therapy of advanced ovarian carcinoma]Jacobus Pfisterer
The Lancet. Oncology|February 2, 2013
Towards individualised treatment in ovarian cancerSven Mahner, Jacobus Pfisterer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Reply to R. Sun et alJacobus Pfisterer, Joern Rau
Seminars in Oncology|May 24, 2006
Management of platinum-sensitive recurrent ovarian cancerJacobus Pfisterer, Jonathan A Ledermann
Current Treatment Options in Oncology|May 1, 2020
Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?Joanna Glajzer, Jacek P Grabowski, Jalid Sehouli, et al.
Immunotherapy|February 17, 2011
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancerRachel N Grisham, Jonathan Berek, Jacobus Pfisterer, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All?Leigh A Cantrell, Jacobus Pfisterer, John Boggess, et al.
Gynecologic Oncology|November 8, 2008
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic reviewAndreas du Bois, Justine Rochon, Jacobus Pfisterer, et al.
Gynecologic Oncology|September 24, 2004
The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter studyEva-Katrin Riener, Norbert Arnold, Friedrich Kommoss, et al.
Onkologie|March 15, 2012
Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experienceFelix Hilpert, Pauline Wimberger, Andreas du Bois, et al.
Pageof 10